Your fact-checks will appear here
Peer-reviewed scientific journal
The available sources show that 2025 ACC/AHA guidance — as reflected in the 2025 Acute Coronary Syndromes (ACS) guideline and related summaries — keeps aggressive lipid management in high-risk and sec...
Brian Ference appears in multiple public roles: as an Arizona-based conservative activist and self-described independent/citizen journalist with a personal site and local political activity , and sepa...
Available studies and regulatory summaries show myocarditis after COVID-19 vaccination is rare, concentrates in males aged ~12–24 and most often occurs within days of a second mRNA dose; FDA cites ~27...
The 2025 guidance landscape continues to direct high‑intensity statins for people with established atherosclerotic cardiovascular disease (ASCVD), those with LDL‑C ≥190 mg/dL, and many patients after ...
The provided reporting does not include a single, explicit table listing "LDL‑C thresholds by 10‑year ASCVD risk" from a 2025 ACC/AHA cholesterol guideline; instead, recent 2025 guideline documents an...
Major cardiology and preventive medicine bodies now advise against routine initiation of low‑dose aspirin for primary prevention in older adults: the U.S. Preventive Services Task Force (USPSTF) recom...
The 2025 ACC/AHA guidance shifts clinicians away from relying solely on the older Pooled Cohort Equations (PCE) for broad primary‑prevention decisions and introduces the PREVENT risk equation as the p...
New 2025 U.S. guidelines set the general blood‑pressure (BP) treatment goal below 130/80 mm Hg and explicitly encourage lowering systolic BP further toward <120 mm Hg when safe; initiation of medicati...
Large post‑authorization surveillance and regulatory summaries from 2023–2025 consistently put myocarditis after mRNA COVID vaccines in the range of single‑digit to a few dozen cases per million doses...
No reputable medical organizations in the provided reporting are shown to endorse SugarWise as a diabetes treatment; SugarWise’s own marketing describes it as a dietary supplement that “should not rep...
No professional medical society endorsement of GlucoSense appears in the available reporting; major diabetes guideline bodies like the American Diabetes Association released 2025 Standards but those d...
The One Big Beautiful Bill Act (OBBBA) does not, in the reporting available here, explicitly say it authorizes private-market “medical underwriting” or broad conditional coverage exclusions; instead i...
The 2025 AHA/ACC multisociety guideline recommends aiming for an office blood pressure (BP) goal of <130/80 mm Hg for most adults with confirmed hypertension, with encouragement to lower systolic pres...
Medicare reimbursement for remote patient monitoring (RPM) cardiac services in 2025 is governed by the 2025 Medicare Physician Fee Schedule (PFS) final rule and related CMS guidance: CMS set the 2025 ...
Major 2024–2025 guidelines and reviews treat diabetes, chronic kidney disease (CKD), and familial hypercholesterolemia (FH) as “statin‑indicated” or risk‑enhancing conditions that lower the threshold ...
Statins are widely prescribed drugs that lower LDL (“bad”) cholesterol and reduce heart attack and stroke risk; clinical reviews and guidelines say they are generally safe but can cause muscle symptom...